TheEdgeResearch
Home / Stocks / GTHP

Guided Therapeutics, Inc. (GTHP)

OTC Healthcare Medical - Devices
$0.10 ▼ -9.09%
Market Cap
$9.7M
Sector
Healthcare
Industry
Medical - Devices
Beta
0.70
52-Wk Range
0.1-0.54
CEO
Mark L. Faupel
Country
US
Currency
USD

Guided Therapeutics, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Peachtree Corners, GA, US. The stock last traded at $0.10, down 9.09% on the session, giving a market capitalisation of $9.7M. On trailing twelve-month figures it carries a trailing P/E of -2.64, a net margin of -543.0%. Its beta of 0.70 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-2.64
Price / Sales
14.16
Price / Book
-1.57
EV / EBITDA
-5.03
Gross margin
69.2%
Operating margin
-326.7%
Net margin
-543.0%
Return on equity
—
Debt / equity
-0.45
Current ratio
0.11
Dividend yield
0.0%
Payout ratio
-1.4%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2021-01-08
Headquarters
Peachtree Corners, GA, US
About Guided Therapeutics, Inc.

Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.

Comparable companies

Guided Therapeutics, Inc. is most often compared with the following Healthcare names:

CYDXMDXHFQTI
More research on GTHP
GTHP technical analysis GTHP TheEdge Score Compare against peers
Open full interactive analysis & DCF →